Ardelyx present additional data at NKF 2024 on XPHOZAH

Ardelyx announced that data supporting additional positive clinical observations of XPHOZAH was presented in a series of poster presentations at the National Kidney Foundation, NKF, 2024 Spring Clinical Meetings, now underway in Long Beach, California. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management. Poster #239, entitled “Tenapanor Treatment Added to Phosphate Binders Improved Long-Term Serum Phosphate Control as Measured by Reduction in Average Daily P Area Under the Curve,” reviewed data from an area under the curve assessment meant to provide a more comprehensive evaluation of serum phosphate levels than individual serum phosphate measurements. Poster #243, entitled “Treatment Response to Tenapanor Categorized by Age and Comorbidities: A Post Hoc Analysis of the PHREEDOM Study,” reported results from a post hoc analysis of the PHREEDOM study to evaluate trends in serum phosphate concentrations in patients on dialysis treated with tenapanor categorized by age and comorbidity status. Tenapanor demonstrated similar efficacy and safety profiles in adult patients on dialysis regardless of age group and comorbidity. Poster #240, entitled “Patient Perception of Phosphate-Lowering Treatment Regimen Improves Adherence to Therapy,” evaluated if an improvement in patient perception of phosphate-lowering treatment may improve adherence to treatment and promote a greater decrease in serum phosphate over time. By the end of the 10-week treatment period, adherence was greater in patients who perceived their treatment regimen to be improved by adding tenapanor and stopping or decreasing their phosphate binder regimen.